MAZ51
Based on 8 publication(s) in Google Scholar
MAZ51 is a selective inhibitor of VEGFR-3 (Flt-4) tyrosine kinase. MAZ51 inhibits VEGF-C-induced activation of VEGFR-3 without blocking VEGF-C-mediated stimulation of VEGFR2. MAZ51 had no effect on ligand-induced autophosphorylation of EGFR, IGF-1R and PDGFRβ. MAZ51 blocks proliferation and induces apoptosis in a wide variety of tumor cells. Antitumor activity.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.76%
- No. CAS: 163655-37-6
- Fòrmula: C21H18N2O
- Peso molecular:314.38
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) MAZ51
More- J Nanobiotechnology. 2025 Jul 16;23(1):522. [Abstract]
- Adv Sci (Weinh). 2025 May 31:e04467. [Abstract]
- Alzheimers Dement. 2025 Jan 30:e14518. [Abstract]
- J Ethnopharmacol. 2026 Feb 28:357:120937. [Abstract]
- Mediators Inflamm. 2023 Apr 21:2023:5679966. [Abstract]
- Exp Neurol. 2024 Jul:377:114783. [Abstract]
- bioRxiv. 2026 May 27.
- Research Square Print. 23 Dec 2022.
Customer Validation & Images
-
In Vivo Imaging
-
Histological Imaging/Staining
-
IF
-
ELISA
-
In Vivo Efficacy Study
Ver todos los productos específicos de isoformas VEGFR
More
Actividad biológica
|
VEGFR3 |
MAZ51 (2.5-10 μM; 24 hours) blocks proliferation and induces apoptosis in a wide variety of tumor cells[2].
MAZ51 (0.5-50 μM; 25 minutes) has no effect on ligand-induced autophosphorylation of EGFR, IGF-1R and PDGFRβ in A431 cells, HEK-293 cells, and PAE cells, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MT450, 1AS, ASM, G, AT6.1, MTLN3, MTLY, NM-081 cells
-
Concentration:2.5, 10 μM
-
Incubation Time:24 hours
-
Result:Induced apoptosis in a wide variety of tumor cells.
-
Cell Line:MT450, 1AS, ASM, G, AT6.1, MTLN3, MTLY, NM-081 cells
-
Concentration:2.5, 10 μM
-
Incubation Time:24 hours
-
Result:Blocked proliferation in a wide variety of tumor cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar Furth rats (bearing MT450 cells)[1]
-
Dosage:8 mg/kg
-
Administration:Intraperitoneal injection; daily for 15 day
-
Result:Significantly suppressed the growth of MT450 tumors.
Chemical Information
-
No. CAS 163655-37-6
-
Appearance Solid
-
Peso molecular 314.38
-
Fòrmula C21H18N2O
-
Color Orange to red
-
SMILES
CN(C1=C2C=CC=CC2=C(C=C1)/C=C3C(NC4=C/3C=CC=C4)=O)C
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years * The compound is unstable in solutions, freshly prepared is recommended.
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
J Nanobiotechnology
Exosomes derived from platelet-rich plasma alleviate synovial inflammation by enhancing synovial lymphatic function. [Abstract]2025 Jul 16;23(1):522. PMID: 40671121
MAZ51 purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2025 Jul 16;23(1):522. [Abstract]
MAZ51 (16 mg/kg; i.p.; every other day). Representative near-infrared (NIR) lymphatic imaging (ICG) of knee joints from each group and quantitative analysis of the lymphatic clearance rate (n = 5).
MAZ51 purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2025 Jul 16;23(1):522. [Abstract]
MAZ51 (16 mg/kg; i.p.; every other day). Representative H&E-stained images of knee joint synovial tissue from each group with synovitis scores. Scale bars: 500 μm and 100 μm.
MAZ51 purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2025 Jul 16;23(1):522. [Abstract]
MAZ51 (16 mg/kg; i.p.; every other day). Immunofluorescence staining of synovial tissue sections from each group, with F4/80 (green), Inos (red), and DAPI (blue). Scale bar: 20 μm.
MAZ51 purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2025 Jul 16;23(1):522. [Abstract]
MAZ51 (16 mg/kg; i.p.; every other day). ELISA analysis of IL-1β and TNF-α levels in synovial tissue from each group. The results showed that significantly increased concentrations in PRP-Exos + MAZ51 group compared to the PRP-Exos + Vehicle group.
-
Adv Sci (Weinh)
A Novel Cranial Bone Transport Technique Repairs Skull Defect and Minimizes Brain Injury Outcome in Traumatic Brain Injury Rats. [Abstract]2025 May 31:e04467. PMID: 40448603
MAZ51 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 May 31:e04467. [Abstract]
Representative Nissl staining and images of gross view of the TBI rats injected with MAZ51 (MAZ51 in dimethyl sulfoxide was dissolved in 20% SBE‐β‐CD and artificial CSF, then loaded into a capsule of the osmotic pump with a total volume of 100 µL, continuously intra‐cisterna magna infusion at 1 mg/kg of body weight for 30 days). Quantification of percentage of lesion size, calculated by ratio of the lesion area in ipsilateral brain to whole area of contralateral brain.
MAZ51 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 May 31:e04467. [Abstract]
MAZ51 in dimethyl sulfoxide was dissolved in 20% SBE‐β‐CD and artificial CSF, then loaded into a capsule of the osmotic pump with a total volume of 100 µL, continuously intra‐cisterna magna infusion at 1 mg/kg of body weight for 30 days. Representative images of perilesional cortex stained with GFAP (green) and Iba1 (red), scale bar = 50 µm.
-
Alzheimers Dement
Cranial bone maneuver ameliorates Alzheimer's disease pathology via enhancing meningeal lymphatic drainage function. [Abstract]2025 Jan 30:e14518. PMID: 39887820 -
J Ethnopharmacol
The regulation of lymphatic valve formation promotes lymphatic drainage to reduce atherosclerotic plaques: A novel mechanism of anti-atherosclerosis by Gualou-Xiebai. [Abstract]2026 Feb 28:357:120937. PMID: 41270912 -
Mediators Inflamm
Tumor Necrosis Factor- α Promotes the Tumorigenesis, Lymphangiogenesis, and Lymphatic Metastasis in Cervical Cancer via Activating VEGFC-Mediated AKT and ERK Pathways. [Abstract]2023 Apr 21:2023:5679966. PMID: 37124061 -
Exp Neurol
Peripheral nervous system lymphatic vessels: A simple delivery route to promote nerve regeneration. [Abstract]2024 Jul:377:114783. PMID: 38688418 -
-
Solvente y solubilidad
DMSO : 8.33 mg/mL (26.50 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.83 mg/mL (2.64 mM); Clear solution
This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 4 mg/mL (12.72 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * The compound is unstable in solutions, freshly prepared is recommended.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (284 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Kirkin V, et al. Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2. Eur J Biochem. 2001 Nov;268(21):5530-40. [Content Brief]
[2]. Kirkin V, et al. MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo. Int J Cancer. 2004 Dec 20;112(6):986-93. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1809 mL | 15.9043 mL | 31.8086 mL | 79.5216 mL |
| 5 mM | 0.6362 mL | 3.1809 mL | 6.3617 mL | 15.9043 mL | |
| 10 mM | 0.3181 mL | 1.5904 mL | 3.1809 mL | 7.9522 mL | |
| 15 mM | 0.2121 mL | 1.0603 mL | 2.1206 mL | 5.3014 mL | |
| 20 mM | 0.1590 mL | 0.7952 mL | 1.5904 mL | 3.9761 mL | |
| 25 mM | 0.1272 mL | 0.6362 mL | 1.2723 mL | 3.1809 mL |
MAZ51 Related Classifications
HY-116624 Related Classifications
Powered by Bioz